Ri Xiang Kong
Chief Tech/Sci/R&D Officer at Beijing Biostar Pharmaceuticals Co. Ltd.
Ri Xiang Kong active positions
| Companies | Position | Start | End |
|---|---|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
 Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Director/Board Member | 2021-02-28 | - |
| Chief Tech/Sci/R&D Officer | 2018-11-30 | - |
Career history of Ri Xiang Kong
Training of Ri Xiang Kong
| Tianjin University of Science & Technology | Graduate Degree |
Statistics
International
| China | 3 |
Operational
| Graduate Degree | 1 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoral
| Consumer Services | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Beijing Biostar Pharmaceuticals Co. Ltd.
Beijing Biostar Pharmaceuticals Co. Ltd. Pharmaceuticals: MajorHealth Technology Beijing Biostar Pharmaceuticals Co. Ltd. engages in the tumor treatment. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by Li Tang and Rong Guo Qiu on July 11, 2002 and is headquartered in Beijing, China. | Health Technology |
- Stock Market
- Insiders
- Ri Xiang Kong
- Experience
